Improving prognostic modeling of prostate cancer through a crowdsourcing competition
University of Turku researchers developed a winning solution for predicting overall survival of patients with metastatic castrate resistant prostate cancer (mCRPC), treated with first-line anti-mitotic chemotherapy. The primary benefit of this Challenge will be to establish new quantitative benchmarks for prognostic modeling in mCRPC, with a potential impact for clinical decision making and ultimately improving the design of future clinical trials.